GLP-1 Medications Are Approved For Many Reasons
The Quick Answer
A licensed provider decides whether a GLP-1 medication is appropriate for you. What the FDA labels define is who each medication is approved for. For weight management in adults, the Wegovy and Zepbound labels cover[2][3]:
- Adults with obesity, which NIDDK describes as a BMI of 30 or higher[1], OR
- Adults with overweight and at least one weight-related condition, which NIDDK describes as a BMI of 27 or higher with weight-related health problems such as high blood pressure or type 2 diabetes[1]
Wegovy injection is also approved for children 12 and older with obesity[2]. Both medications are approved for use with a reduced-calorie diet and increased physical activity.
Meeting these criteria does not mean a prescription is appropriate. A licensed provider reviews your full medical history, current medications, and health conditions before deciding, and the answer can be no.
What Is BMI, and Why Does It Matter?
Your Body Mass Index (BMI) is calculated from your weight and height. It is a screening measure, and NIDDK notes that health care professionals use it to help decide whether someone might benefit from weight management medications[1]. Providers use it alongside other clinical information.
BMI = weight in pounds / (height in inches squared) x 703
You can calculate your BMI using any online calculator. NIDDK defines obesity as a BMI of 30 or greater, and overweight as a BMI between 25 and 30[1].
The BMI 30+ Rule (Obesity)
A BMI of 30 or higher is the obesity category by medical definition[1], and adults with obesity fall within the weight management indications on the Wegovy and Zepbound labels[2][3]. No additional health condition is part of that indication.
A BMI of 30 or higher alone does not mean a prescription is appropriate. A provider still considers:
- Your complete medical history
- Current medications and any potential interactions
- Label contraindications and warnings (see below)
- Your goals and what follow-up the treatment involves
- Overall clinical appropriateness
The BMI 27-29.9 Rule (Overweight With a Condition)
A BMI from 27 to 29.9 falls in the overweight category. The Wegovy and Zepbound labels cover adults with overweight who have at least one weight-related condition[2][3].
Examples of Weight-Related Health Conditions
The labels do not publish a complete list of weight-related conditions. NIDDK gives high blood pressure and type 2 diabetes as examples[1], and the main trials described in the labels enrolled people with conditions such as[2][3]:
- High blood pressure (hypertension)
- Abnormal cholesterol or triglycerides (dyslipidemia)
- Obstructive sleep apnea
- Cardiovascular disease, such as a prior heart attack, prior stroke, or peripheral arterial disease
Type 2 diabetes was studied in separate trials. Whether a condition counts in your situation, and whether a medication is appropriate, is the provider’s decision.
Approved Uses Beyond Weight Management
Some of these medications have other FDA-approved uses, each with its own criteria[2][3]:
- Cardiovascular risk: Wegovy (injection and tablets) is approved to reduce the risk of major cardiovascular events (cardiovascular death, heart attack, or stroke) in adults with established cardiovascular disease and either obesity or overweight.
- Liver disease (MASH): Wegovy injection is approved to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults. This approval is an accelerated approval, and continued approval may depend on a confirmatory trial.
- Sleep apnea: Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity.
How Common Weight-Related Conditions Are Defined
These are standard definitions from professional guidelines, so you can understand what a provider may ask about. Each provider applies their own clinical judgment, and the labels do not set thresholds for these conditions.
Hypertension (High Blood Pressure)
The 2017 American College of Cardiology and American Heart Association guideline defines hypertension as a systolic blood pressure (the top number) of 130 mmHg or higher, or a diastolic blood pressure (the bottom number) of 80 mmHg or higher[6]. A provider may ask about recent readings, a diagnosis, or blood pressure medication you take.
Type 2 Diabetes or Prediabetes
The American Diabetes Association uses these cutoffs[7]:
- Diabetes: HbA1c of 6.5% or higher, or fasting glucose of 126 mg/dL or higher
- Prediabetes: HbA1c between 5.7% and 6.4%, fasting glucose between 100 and 125 mg/dL, or a 2-hour glucose of 140 to 199 mg/dL on an oral glucose tolerance test
A provider may ask for recent lab results.
Dyslipidemia (High Cholesterol or Abnormal Lipids)
Dyslipidemia means abnormal levels of cholesterol or triglycerides on a lipid panel, such as high LDL (“bad”) cholesterol, high triglycerides, or low HDL (“good”) cholesterol. A provider may ask for a recent lipid panel or about cholesterol medication you take.
Sleep Apnea (Obstructive Sleep Apnea)
Obstructive sleep apnea is usually diagnosed with a sleep study. A provider may ask for the study report or whether you use a CPAP machine. Zepbound’s sleep apnea indication covers moderate to severe obstructive sleep apnea in adults with obesity[3].
Polycystic Ovary Syndrome (PCOS)
PCOS is commonly diagnosed using the Rotterdam criteria, which require two of these three findings[8]:
- Irregular or absent ovulation
- Clinical or lab signs of elevated androgens (such as excess facial or body hair, or high testosterone)
- Polycystic ovaries on ultrasound
PCOS is not named in the Wegovy or Zepbound indications. People with PCOS often have related metabolic conditions, such as insulin resistance, high blood pressure, or abnormal cholesterol. Whether these count in your situation is the provider’s decision.
Cardiovascular Disease
In the Wegovy cardiovascular trial described in the label, established cardiovascular disease meant a prior heart attack, prior stroke, or peripheral arterial disease[2]. A provider may ask for records that confirm a diagnosis.
Additional Metabolic Conditions
- Metabolic syndrome: A cluster of conditions such as high blood pressure, high blood sugar, abnormal cholesterol or triglycerides, and a large waist measurement.
- Fatty liver disease (MASLD): Fat buildup in the liver, usually found on imaging or blood tests. Its more advanced form, MASH, is a separate Wegovy indication when moderate to advanced fibrosis is present[2].
Important Note on Clinical Judgment
These definitions are a framework, not a checklist. A provider looks at the overall clinical picture. A reading near a cutoff may or may not matter, and meeting one definition does not mean a medication is appropriate if other medical factors apply.
Type 2 Diabetes and GLP-1 Medications
Type 2 diabetes is one of the weight-related conditions NIDDK names[1]. Some GLP-1 medications are FDA-approved separately for type 2 diabetes: Ozempic injection to improve blood sugar control in adults with type 2 diabetes[4], and Mounjaro to improve blood sugar control in adults and children 10 and older with type 2 diabetes[5]. If you have diabetes, the labels advise monitoring blood sugar, and taking a GLP-1 with insulin or a sulfonylurea can raise the risk of low blood sugar[2][3]. A provider decides which medication, if any, fits.
Clinical Evaluation Is Always Required
Even if your BMI and health conditions match a label indication, a licensed provider reviews your health information before a prescription can be written. A proper process is not a rubber stamp.
At most programs and offices, the provider looks at:
- Full medical history – All conditions, treatments, and surgeries
- Current medications and supplements – To check for interactions or reasons not to use a GLP-1 medication
- Medication allergies and reactions – Your history with other drugs
- Contraindications and warnings – Reasons in the label that a medication may not be appropriate (see “Who Should Not Use These Medications” below)
- Goals and expectations – What outcomes are reasonable for your situation
- Follow-up – How dose increases, side effects, and renewals will be handled
Not everyone whose BMI matches a label indication is a good fit for a GLP-1 medication, and the provider review is how those situations are identified.
Who Should Not Use These Medications
The FDA labels list who should not use these medications and the warnings a provider weighs[2][3].
Label Contraindications
Both the Wegovy and Zepbound labels say the medication should not be used by people with:
- A personal or family history of medullary thyroid carcinoma (MTC) – Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) – For the same reason.
- A known serious allergy to the medication – Hypersensitivity to semaglutide or tirzepatide, or to any ingredient in the product.
Label Warnings a Provider Weighs
These are not automatic exclusions, but a provider considers them:
- Pregnancy – Both labels say these medications may cause fetal harm and to stop when pregnancy is recognized (for Wegovy, when used for weight or cardiovascular risk). The Wegovy label says to stop at least 2 months before a planned pregnancy.
- Severe gastroparesis – Both labels say the medication is not recommended in people with severe gastroparesis (very slow stomach emptying).
- Pancreatitis – Acute pancreatitis has been seen with GLP-1 medications. Tell the provider if you have had it.
- Gallbladder disease – Gallbladder problems have occurred in clinical trials.
- Diabetic retinopathy – The labels warn about diabetic retinopathy complications in people with type 2 diabetes.
- Kidney problems – Vomiting or diarrhea can lead to dehydration and kidney injury; the labels advise monitoring kidney function in that situation.
- Surgery or sedation – The labels warn about a risk of inhaling stomach contents during general anesthesia or deep sedation. Tell anyone doing a procedure that you take a GLP-1.
The most common side effects in the labels include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, fatigue, and hair loss. Read the full prescribing information and ask the prescriber about your own risks.
Medication Interactions
A provider reviews all current medications and supplements. The labels note[2][3]:
- Insulin or a sulfonylurea – Taking these with a GLP-1 can raise the risk of low blood sugar, so the dose may need to be lowered.
- Oral medications – GLP-1 medications slow stomach emptying, which can affect how other pills are absorbed.
- Oral birth control (Zepbound) – The Zepbound label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.
- Other GLP-1 products – Using these medications with another semaglutide, tirzepatide, or GLP-1 product is not recommended.
An interaction does not always rule out a medication. Often it means a dose change or closer monitoring, and the provider decides whether the risks are manageable.
State-Specific Requirements
Whether a live video or phone visit is required before a GLP-1 prescription is written depends on the program and on the state where you are located. Some telehealth programs prescribe after reviewing a health history form, and others require a live visit in some or all states. A provider can also ask for a live visit when they think it is needed.
Rules change, so check with the program rather than relying on a list. Before you pay, ask:
- Is a live visit required in my state, and is it included in the price?
- Is the prescriber licensed in the state where I live? (You can look this up on your state’s medical, nursing, or physician assistant board website.)
Transformation Health does not accept payment from providers. How we make money.
What a Health History Form Usually Asks
Whether you see your primary care provider or use a telehealth program, expect questions about:
- Height and weight – Used to calculate your BMI
- Current health conditions – Diabetes, high blood pressure, heart disease, sleep apnea, high cholesterol, and others
- Medications and supplements – Everything you take, including doses
- Allergies – Anything you have had an allergic reaction to
- Surgical history – Any major surgeries or procedures
- Weight history – Previous attempts, what worked or did not, and current goals
- Thyroid history – Any personal or family history of medullary thyroid carcinoma or MEN 2
- Pregnancy status – Whether you are pregnant, breastfeeding, or planning pregnancy
Answer fully. The provider can only judge what you share. Before you submit a form online, check who sees your answers, how the program says it stores and uses your information, and whether you pay anything before a provider reviews your history.
How the process should work
At most programs and offices, the steps look like this:
- You share your health history – On a form or at a visit.
- A licensed provider reviews it – A physician, nurse practitioner, or physician assistant reviews your history and decides whether a GLP-1 medication is appropriate. Some programs require a live visit first.
- You hear the decision – If the provider decides a medication is appropriate, you get information about the prescription and next steps. If not, a proper program explains why.
- A pharmacy fills the prescription – Brand-name medications are filled by a retail or mail-order pharmacy, and insurance may require prior authorization. Compounded medications are prepared by a state-licensed compounding pharmacy or an FDA-registered outsourcing facility and are usually shipped to your home. Compounded medications are not FDA-approved.
- Follow-up continues – Dose increases, side effect questions, and renewals are handled by a licensed provider.
Timelines vary by program, insurance, and pharmacy. Ask for the program’s own published terms, and ask what you pay if no prescription is written.
Label Criteria at a Glance
This summary restates the label indications and contraindications. It does not tell you whether a medication is appropriate for you; a licensed provider decides that.
| Situation | What the labels say |
|---|---|
| Adult with BMI 30 or higher | Within the Wegovy and Zepbound weight management indications[1][2][3] |
| Adult with BMI 27 to 29.9 and a weight-related condition | Within the Wegovy and Zepbound weight management indications[1][2][3] |
| Child 12 or older with obesity | Within the Wegovy injection indication; Zepbound’s weight indication is for adults[2][3] |
| Adult with established cardiovascular disease and obesity or overweight | Wegovy is also approved to reduce the risk of major cardiovascular events[2] |
| Adult with moderate to severe obstructive sleep apnea and obesity | Zepbound is also approved to treat sleep apnea[3] |
| Personal or family history of MTC, or MEN 2 | Contraindicated (should not be used)[2][3] |
| Known serious allergy to the medication | Contraindicated[2][3] |
| Pregnant or planning pregnancy | Stop when pregnancy is recognized; Wegovy label says stop at least 2 months before a planned pregnancy[2][3] |
| Severe gastroparesis | Not recommended[2][3] |
Key Points to Remember
BMI is a starting point, not the whole story. BMI shows whether you match a label indication, but the provider’s clinical judgment determines whether the medication is appropriate for you.
No guarantees. Even if your BMI matches the label criteria, a provider may decide a GLP-1 medication is not appropriate based on your health history, medications, or other factors. That is not a failure on your part; it is the provider being careful.
Ask about costs before you start. Ask any program what you pay if no prescription is written, and compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.
You are not alone. Many adults looking at weight management medication have already tried several approaches. A provider evaluation is how you find out whether medication is a medically appropriate next step for you.
Results vary by individual. Results depend on many factors, including diet, activity, medical history, and how your body responds. Trial results describe study participants and are not a prediction for any individual.
Next Steps
If you are thinking about a GLP-1 medication:
- Pick a route – Your primary care provider, a telehealth program, or an in-person clinic.
- Bring your questions – If you have a condition or medication you are unsure about, ask the provider before you pay for anything.
- Check the prescriber and pharmacy – Confirm the prescriber is licensed in your state and the pharmacy is licensed to fill or ship your prescription.
A licensed provider decides whether a prescription is appropriate for you.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedImportant disclosures
This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro, and they may differ in formulation, purity, and potency.
Results vary. Trial results describe study participants and are not a prediction for any individual.
Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.
Citations
[1] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight & Obesity.” Last reviewed June 2024. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity (Accessed 2026-10-16.)
[2] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, Prescribing Information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[3] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, Prescribing Information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[4] U.S. Food and Drug Administration. OZEMPIC (semaglutide) injection, Prescribing Information. Revised 05/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637Orig1s039lbl.pdf
[5] U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, Prescribing Information. Revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf
[6] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065
[7] American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19-S40. doi:10.2337/dc23-S002
[8] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41-47. doi:10.1093/humrep/deh098
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency. Results vary. Transformation Health does not accept payment from providers. How we make money.